Successful imaging or treatment of neuroblastoma With '3'I-meta-iodobenzy1guanidine depends on the selectivity of active (type 1) uptake of mIBG in neuroblastoma cells relative to passive (type 2) uptake present in most normal tissues. This study investigates the effects of moderately elevated temperature (39-41'C) on the cellular uptake of '3'I-mIBG in two neuroblastoma cell lines [SK-N-BE(2c) and and in a non-neuronal (ovarian carcinoma) cell line (A2780). In SK-N-BE(2c), a cell line with high active uptake capacity. the specific (type 1) uptake was reduced by 75% (P<0.001) at 39"C. Both IMR-32 and A2780 have a low capacity for accumulation of mIBG by active uptake. These cell lines demonstrated a statistically significant increase in accumulation at 39C, mainly as a result of increased non-specific transport.
Suvival rates in neuroblastoma. the most common extracranial solid paediatric malignancy, have been improving less rapidly than in other childhood tumours (Stiller & Bunch. 1990) . Neuroblastoma is often widespread at diagnosis: 75% of older children present with advanced disease. The prognosis of this group is especially disappointing, with less than 20% surviving 2 years.
At present. first-line chemotherapy induces remission in approximately 40% of patients. but about half of these will relapse. To improve the survival of this group, consolidation treatment using high-dose chemotherapy and bone marrow rescue, with or without total body irradiation (TBI), is used. Neuroblastoma is a relatively radiosensitive tumour, but the dose administered by external beam radiation during fractionated TBI is limited by normal tissue toxicity to about 14.4 Gy. which is probably insufficient for eradication of macroscopic disease (Steel & Wheldon. 1992 ).
An alternative means of selective delivery of therapeutic radiation to neuroblastoma employs the radiopharmaceutical '3I-meta-iodobenzylguanidine (mIBG) . This compound, a guanethidine and bretylium analogue (Wieland et al., 1980) , is preferentially accumulated by cells of sympathetic nerve origin via the noradrenaline uptake mechanism. This mechanism is a characteristic of catecholamine-synthesising cells such as adrenergic nerves and chromaffin cells (Jacques et al., 1987) . This specific uptake process has been well characterised in a number of neuroblastoma cell lines in culture (Buck et al., 1985; Lashford et al., 1991; Mairs et al., 1991) . The use of mIBG for diagnostic imaging and targeted radiotherapy of neuroblastoma and phaeochromocytoma exploits this mechanism (Hoefnagel et al., 1987) .
The critical requirement for any form of targeted radiotherapy is preferential uptake of the targeting agent by tumour cells relative to normal tissues. In this case, fulfilment of this condition requires high active uptake (type 1) in neuroblastoma cells relative to the passive (type 2) uptake which occurs in normal as well as tumour cells. Clinically, neuroblastomas differ markedly in their active uptake of mlBG (Moyes et al., 1989) , making them of variable suitability for ''I-mIBG treatment. Little is yet known of the factors which control active uptake and how it can be modified.
The effectiveness of combining '3'I-mIBG with elevated Information gained from experiments involving temperatures slightly greater than 37°C might be useful in predicting the likely effect of increased temperature on active and passive uptake of mIBG in higher temperature situations in which concomitant cell sterilisation and lysis is a complicating factor. We have therefore measured the uptake of "'I-mIBG by two neuroblastoma cell lines at three temperatures -37°C 39'C and 41'C -using an ovarian cancer cell line as a non-neuronal control. To differentiate between active (type 1) uptake and passive (type 2) accumulation, experiments were performed in the presence or absence of a tricyclic antidepressant, desmethylimipramine. This prevents the reuptake of neurotransmitters by adrenergic neurones and has previously been shown to inhibit type 1 active uptake (Mairs et al., 1991) .
Materials and methods

Cell culture
Two well-established neuroblastoma cell lines. SK-N-BE(2c) (Biedler et al., 1978) and IMR-32 (Tumilowicz et al.. 1970) , were used. These lines were chosen as they represent extremes of mIBG uptake ability. The ovarian cell line A2780. a variant of the cell line NIH:OVCAR-3, was used as a non-regularly srened to ensure absnce of mycoplasma contamination and were grown at 37C, in 5% carbon dioxide.
SK-N-BE(2c) and A2780 were cultured in RPMI-1640 medium with 25 mM HEPES buffer and supplemented with 10% fetal calf serum, penicillin and streptomycin (100 IU ml-1), 2 mM L-glUtamine, 2mM amphotericin and 2 mM non-essential amino acids. IMR-32 was grown in
Ham's FIO medium with glutamine and the supplements listed above. In addition, A2780 required 0.1% (v/v) insulin (Boehringer Mannheim). All media and suppklments were purchased from Gibco (Paisley, UK) unless otherwise stated.
When in exponential growth the cells were harvested: SK-N-BE(2c) and A2780 required trypsinisation, but IMR-32 cells were readily dislodged from culture vessels by shaking. The cells were then subcultured into 25cm2 plastic tissue culture flasks at an initial density of 0.3 million cells per flask. When these cell monolayers were approximately 70% confluent, they were assayed for '3'I-mIBG uptake.
Reagents '311-meta-iodobenzylguanidine (131I-mIBG) (specific activity 37-185mBqmg-') was obtained from Amersham International (product code IBS 6711). Desmethylimipramine hydrochloride (DMI) was purchased from Sigma (Poole, Dorset, UK).
'31I-mIBG uptake All chemicals and media were first heated to the desired temperature. Cells were incubated with or without 1.5 IM DMI for 30min. This duration of the preincubation and concentration of DMI used was previously shown to demonstrate maximal drug inhibition of type 1 active transport (Mais et al., 1991) . At the end of this period, the medium was replaced by one containing 0.1 mM 13'I-mIBG with or without DMI. The cells were then incubated for a maximum of 2 h at 37C, 39-C or 41-C. Experiments were performed in thermostatically controlled water baths for maximum accuracy. All solutions and media were first equilibrated to the desird temperature before use. The temperature of the flasks was meticulously checked throughout the experiments.
In order to measure '311-mIBG uptke, the uptake process was first terminated by washing with ice-cold phosphatebuffered saline. The radioactive lysate was then extracted from the cells by two 0.5-ml aliquots of 10% (w/v) trichloroacetic acid and measured in a sodium iodide crystal gamma counter (Canberra Packard, Berkshire, UK). Cells were harvested and counted and a mean number of cells caulated for each flask.
Cell survival experiments Cell survival was ass by clonogenic assay. Cells were plated into sterile 25 cm2 flasks at an initial concentration of 1,000 cells per flask. They were incubated for 2 h at 3rC, 39-C or 41-C and then at 37C in 5% carbon dioxide to allow colony formation. After 8-11 days the colonies were fixed with ethanol and stained with Giemsa solution. Colonies of 50 or more cells were counted. The surviving fraction was calculated as the number of colony-forming cells in a treated group, relative to the control, corrected for plated cell number.
Statistical analysis Each experiment was repeated at least three times and six replicates taken for each uptake point in the assay of mIBG uptake. The data (Figure 1 
Reskts
At 3rC, comparison of the incorporation of 13'I-mIBG, at a concentration of 0.1 mM, into SK-N-BE(2c) cells in the presence or absence of 1.5mM DMI (Figure la ) indicated that about 98% was due to active uptake 1. At higher temperatures there was a dramatic, statistically significnt reduction in type 1 intracellular drug accumulation (P<0.001). The inhibitory effect of the 41C incubation on type I uptake was slightly greater than that of 39C (P<0.02). DMI was added to the medium to obtain inhibition of specific transport. Elevated temperature had no significant effect on the non-specific uptake by SK-N-BE(2c) cells. It appears that the temperature-mediated decrease in '3I-mIlBG uptake by SKNBE(2c) was a result of thermal denaturation of the mIBG transporter molecule. IMR-32 cells demonstrated low-level acquisition of 131j-mIBG: approximately 10% of SK-N-BE(2c) levels throughout the 2 h time course. In this cell line we observed ( Figure   lb ) a 3-fold increase in drug accunulation at 39C compared with that at 37C after 1.5h (P<0.001).
A2780 was used as a non-neuronal control (Figure lc) . A similar but less pronounced temperature effect was noted in the '3'I-mIBG entry into these cells. The increase in accumulation at 39C compared with that at either 3rC or 41C was nonetheless highly significant (P<0.001).
Clonogenic cell survival studies demonstrated no temperature dependence of survival for all three cell lines in the range of 39-41C. mIBG is a valuable agent which has potential for use, in combination with other treatments, with curative intent. It is used therapeutically for the targeted radiotherapy of neuroblastoma and phaeochromocytoma (Hoefnagel et al., 1987) , and encouraging but variable results have been seen. The therapeutic potential is limited by variation in uptake: some individual tumours show poor accumulation of mIBG (Moyes et al., 1989) .
The cell line SK-N-BE(2c) demonstrated active, specific type 1 uptake of '31I-mIBG, which has been well charactenised elsewhere (Lashford et al., 1991) .
Neuroblastoma cells retain high intracellular levels of mIBG by a dynamic equilibrium of diffusion and re-uptake (Smets et al., 1990) . If mIBG were given with hyperthermia, heat denaturation of the monoamine receptor ATPase might (if irreversible) diminish the tumour uptake of administered mIBG or inhibit the re-uptake of egressed drug.
We found that the active accumulation of mlBG by SK-N-BE(2c) cells was markedly reduced by eklvated temperature.
One possible explanation is that the transport protein may have been structurally altered at 39-C and 41-C. This is plausible as it has been shown previously that some membrane proteins can undergo a thermotropic transition starting at 39-C (Verma et al., 1977) . In addition, the ability of the Ca-ATPase of sarcoplasmic reticulum to transport calcium has been shown to be reduced at 40-45-C (Cheung et al., 1987) . Na+,K+-ATPases (Szmigielski & Janiak, 1978) as well as other membrane transport systems (Kwock et al., 1978) have been shown to be inhibited at temperatures greater than 43-C. The effect of temperature alteration on the radiopharmaceutical uptake by the cell line IMR-32 was less clear. Since these cells have poor uptake 1 capacity and the elevated temperature-dependent enhnement of mIBG uptake was observed both in the presence and absence of the monoamine transport inhibitor DMI, the increased accumulation of mIBG at 39-C seems to involve non-specific uptake mechanisms. A similar effect of temperature elevation has been noted for passive molcular transport (Strom et al., 1973) in Ehrlic ascitic tumour cells. These exhibit an exponential increase in passive diffusion of radiolabelled uridine across the cell membrane with increasng temperature. Although the effects were marked at 44C the data also support increased passive diffusion at 41C and below. Mechanisms of mlBG uptake which do not involve the noradrenaline receptor are not yet well elucidated but may involve electrochemical gradients (Lampidis et al., 1989) . It has been shown that an abrupt reduction of membrane potential associated with an increased alkcali cation permeability occurs at temperatures greater than 38-C in human erythrocytes (Mikkelson & Wallach, 1977) . As mIBG exists in cationic form at physiological pH, some of the entry into cells incubated at temperatures greater than 3TC could be due to eklctrophoretic migration mediated by altered electrochemical gradients.
The observed incrae in uptake of radiopharmaceutical at 39 C by both IMR-32 and the non-neuronal control cell suggests that a non-specific general effect on the cell membrane may operate at this temperature. The membrane effects of hyperthermia are extensively studied and have been reviwed elsewhere (McLaren & Pontiggia, 1990; Marcocc & Mondovi, 1990) . In general, these changes are mediated by a change in conformation of membrane proteins rather than by changes in lipid motion or order (Lepocc, 1982) .
In the present experiments the uptake of '3'I-mlBG at 41-C was poor in all cell lines, probably because of the denaturation of critical membrane proteins.
We conclude, therefore, that hyperthermia should not be combined with targeted '311-mIBG in tumours in which good uptake of the radiopharmaceutical is anticipated as this may lead to an increased accumulation in non-target tissues and hence a lower therapeutic differential. Further studies are warranted to determine whether or not the increased uptake of mIBG seen at moderately increased temperature (39C) in poorly uptaking cells can lead to an improved therapeutic differential.
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